Evidence map›Paper›PMID 40388626›Full record

ArticleProceedings of the National Academy of Sciences of the United States of America2025

Induction of the ISR by AB5 subtilase cytotoxin drives type-I IFN expression in pDCs via STING activation.

Daniela Barros, Beatriz H Ferreira, Paulina Garcia-Gonzalez, Francesco Carbone, Marine Luka, Fátima Leite-Pinheiro, Mariana D Machado, Theopisti Nikolaou, Angelo Pilotti, Eliot Goguet and 20 more

Abstract read
In one paragraph

Article in Proceedings of the National Academy of Sciences of the United States of America, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Induction of the ISR by AB5 subtilase cytotoxin drives type-I IFN expression in pDCs via STING activation.Proceedings of the National Academy of Sciences of the United States of America · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

30 authors.

Daniela Barros *Institute of Biomedicine, Department of Medical Sciences, University of Aveiro, Aveiro 3810-193, Portugal.
Beatriz H Ferreira *Institute of Biomedicine, Department of Medical Sciences, University of Aveiro, Aveiro 3810-193, Portugal.
Paulina Garcia-GonzalezAix Marseille Université, CNRS, INSERM, Centre d'Immunologie de Marseille-Luminy (CIML), U2, UMR7280 and U1104, Marseille 13288 Cedex 9, France.
Francesco CarboneUniversité de Paris Cité, Imagine Institute, Laboratory of Inflammatory Responses and Transcriptomic Networks in Diseases, Atip-Avenir Team, INSERM U1163, Paris F-75015, France.
Marine LukaUniversité de Paris Cité, Imagine Institute, Laboratory of Inflammatory Responses and Transcriptomic Networks in Diseases, Atip-Avenir Team, INSERM U1163, Paris F-75015, France.
Fátima Leite-PinheiroInstitute of Biomedicine, Department of Medical Sciences, University of Aveiro, Aveiro 3810-193, Portugal.ORCID 0000-0002-8820-8062
Mariana D MachadoInstitute of Biomedicine, Department of Medical Sciences, University of Aveiro, Aveiro 3810-193, Portugal.ORCID 0000-0001-6421-9309
Theopisti NikolaouAix Marseille Université, CNRS, INSERM, Centre d'Immunologie de Marseille-Luminy (CIML), U2, UMR7280 and U1104, Marseille 13288 Cedex 9, France.
Angelo PilottiAix Marseille Université, CNRS, INSERM, Centre d'Immunologie de Marseille-Luminy (CIML), U2, UMR7280 and U1104, Marseille 13288 Cedex 9, France.
Eliot GoguetAix Marseille Université, CNRS, INSERM, Centre d'Immunologie de Marseille-Luminy (CIML), U2, UMR7280 and U1104, Marseille 13288 Cedex 9, France.
Paulo AntasInstitute of Biomedicine, Department of Medical Sciences, University of Aveiro, Aveiro 3810-193, Portugal.ORCID 0000-0002-4361-8164
Andreia MendesInstitute of Biomedicine, Department of Medical Sciences, University of Aveiro, Aveiro 3810-193, Portugal.
Lichen ZhangSchool of Medical Technology, Henan Key Laboratory of Immunology and Targeted Therapy, Xinxiang Medical University, Xinxiang 453003, People's Republic of China.
Marina CresciAix Marseille Université, CNRS, INSERM, Centre d'Immunologie de Marseille-Luminy (CIML), U2, UMR7280 and U1104, Marseille 13288 Cedex 9, France.
Lou GalliotAix Marseille Université, CNRS, INSERM, Centre d'Immunologie de Marseille-Luminy (CIML), U2, UMR7280 and U1104, Marseille 13288 Cedex 9, France.
Julien P GiganAix Marseille Université, CNRS, INSERM, Centre d'Immunologie de Marseille-Luminy (CIML), U2, UMR7280 and U1104, Marseille 13288 Cedex 9, France.
Marisa ReverendoInstitute of Biomedicine, Department of Medical Sciences, University of Aveiro, Aveiro 3810-193, Portugal.
Bing SuShanghai Institute of Immunology, Department of Microbiology and Immunology, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, People's Republic of China.ORCID 0000-0003-0871-7666
Miwako NaritaLaboratory of Hematology and Oncology, Graduate School of Health Sciences, Niigata University, Niigata 951-8518, Japan.
Adrienne W PatonResearch Centre for Infectious Diseases, Department of Molecular and Biomedical Science, University of Adelaide, Adelaide, SA 5005, Australia.
James C PatonResearch Centre for Infectious Diseases, Department of Molecular and Biomedical Science, University of Adelaide, Adelaide, SA 5005, Australia.
Stéphane RocchiUniversité Côte d'Azur, INSERM, Nice U1065, France.
Frédéric Rieux-LaucatUniversité de Paris Cité, Imagine Institute Laboratory of Immunogenetics of Pediatric Autoimmune Diseases, INSERM UMR 1163, Paris 75015, France.ORCID 0000-0001-7858-7866
Rafael J ArgüelloAix Marseille Université, CNRS, INSERM, Centre d'Immunologie de Marseille-Luminy (CIML), U2, UMR7280 and U1104, Marseille 13288 Cedex 9, France.
Béatrice NalAix Marseille Université, CNRS, INSERM, Centre d'Immunologie de Marseille-Luminy (CIML), U2, UMR7280 and U1104, Marseille 13288 Cedex 9, France.
Yinming LiangSchool of Medical Technology, Henan Key Laboratory of Immunology and Targeted Therapy, Xinxiang Medical University, Xinxiang 453003, People's Republic of China.ORCID 0000-0001-9174-4037
Mickaël MénagerUniversité de Paris Cité, Imagine Institute, Laboratory of Inflammatory Responses and Transcriptomic Networks in Diseases, Atip-Avenir Team, INSERM U1163, Paris F-75015, France.
Evelina GattiInstitute of Biomedicine, Department of Medical Sciences, University of Aveiro, Aveiro 3810-193, Portugal.ORCID 0000-0002-0667-0799
Catarina R AlmeidaInstitute of Biomedicine, Department of Medical Sciences, University of Aveiro, Aveiro 3810-193, Portugal.ORCID 0000-0001-6670-6004
Philippe PierreInstitute of Biomedicine, Department of Medical Sciences, University of Aveiro, Aveiro 3810-193, Portugal.ORCID 0000-0003-0863-8255

Funding

Agence Nationale de la Recherche (ANR) AAPG2021-STIMEU Horizon MSCA) program IMMERGE 101119927Fondation pour la Recherche Médicale (FRM) EQU202403018055Fundo Regional para a Ciência e Tecnologia (FRCT) 2022.03217.PTDC
6 · The paper itself

Abstract

We demonstrate that exposure to the AB5 subtilase cytotoxin (SubAB) induces the unfolded protein response (UPR) in human peripheral blood mononuclear cells, concomitant with a proinflammatory response across distinct cell subsets. Notably, SubAB selectively induces type-I interferon (IFN) expression in plasmacytoid dendritic cells, acting synergistically with Toll-like receptor 7 stimulation. The induction of type-I IFN in response to SubAB relies on stimulator of interferon genes (STING) activation, coupled with protein synthesis inhibition mediated by protein kinase R-like endoplasmic reticulum kinase (PERK) and phosphorylation of the eukaryotic translation initiation factor 2 subunit-alpha. By impeding mRNA translation through the integrated stress response, SubAB precipitates the downregulation of the negative innate signaling feedback regulator Tax1-binding protein 1. This downregulation is necessary to unleash TANK-binding kinase 1 signaling associated with STING activation. These findings shed light on how UPR-inducing conditions may regulate the immune system during infection or pathogenesis.

Indexed as

Dendritic CellsEscherichia coli ProteinsInterferon Type IMembrane ProteinsSubtilisinseIF-2 KinaseHumansImmunity, InnateLeukocytes, MononuclearPhosphorylationProtein Serine-Threonine KinasesSignal TransductionSTING ProteinUnfolded Protein ResponseeIF-2 KinaseEscherichia coli ProteinsInterferon Type IMembrane ProteinsProtein Serine-Threonine KinasesSTING1 protein, humanSTING Proteinsubtilase cytotoxin, E coliSubtilisinsinnate immunitypDCsubtilase cytotoxinunfolded protein stress response

Identifiers

PMID40388626
PMCPMC12130819

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.